Latest News and Press Releases

LONDON, June 7, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) announces that it has started a phase II trial of its vascular disrupting agent AS1404 in recurrent ovarian cancer. This...

LONDON and HANAU, Germany, June 2, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) announces that it has signed an agreement with German specialist manufacturer Heraeus to provide...

LONDON, May 23, 2005 (PRIMEZONE) -- Antisoma plc (LSE:ASM) today announces that its Chief Executive Officer, Glyn Edwards, will be presenting at the Needham & Company Fourth Annual Biotechnology...

LONDON and ORLANDO, Fla., May 16, 2005 (PRIMEZONE) -- American Society of Clinical Oncology Meeting -- Cancer drug developer Antisoma (LSE:ASM) announces the presentation at ASCO of promising phase I...

LONDON, May 16, 2005 (PRIMEZONE) -- American Society of Clinical Oncology Meeting, Orlando, Fla., -- Cancer drug developer Antisoma (LSE:ASM) announces the presentation at ASCO of positive phase I...

LONDON, May 5, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) today announces that it plans to expand and accelerate trials of its aptamer drug AS1411, following an internal review of...

LONDON and BOSTON, May 4, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) yesterday presented preclinical data showing the strong anti-cancer potential of its aptamer drug AS1411...

LONDON, April 29, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) today announces that its Chief Executive Officer, Glyn Edwards, will be presenting at the Rodman & Renshaw...

-- U.S. IND granted for phase II study in prostate cancer -- AACR presentations on Antisoma's AS1404: promising prostate and ovarian cancer data support trial plans LONDON, April 19, 2005...

ANAHEIM, Calif. and LONDON April 18, 2005 (PRIMEZONE) -- American Association of Cancer Research Meeting in Anaheim, California -- Cancer drug developer Antisoma plc (LSE:ASM) today presents the...